Abstract
New genome editing technologies are playing an increased role in an array of advanced research and development efforts in the life sciences. In tandem, there has been broad recognition of the need to address the ethical issues associated with the use of these genome editing tools. Although many uses of genome editing technologies do not raise novel ethical concerns, some have rightly attracted considerable attention, especially regarding the possibility of manipulating the human germline. Such concerns have prompted a substantial body of scholarship and high-profile efforts to address these ethics and policy matters. While the outcomes of these deliberations offer useful high-level advice, there has been little discussion of the critical ethical issues involved with the practical processes of manufacture, sale, and distribution of genome editing technology products that enable this research. Here, we describe these issues and practices being developed and implemented to address them.